{"entity":{"id":"paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022","kind":"paper","name":"AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma","aka":[],"tldr":"Swapping bleomycin for the antibody-drug conjugate brentuximab vedotin in children's chemotherapy for advanced Hodgkin lymphoma cut the risk of relapse or death by 59 percent with no extra toxicity.","summary":"Open-label multicentre randomised phase 3 trial: 600 patients aged 2 to 21 with untreated high-risk classical Hodgkin lymphoma were assigned to five cycles of brentuximab vedotin with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide or to standard ABVE-PC, with PET-directed involved-site radiotherapy to slow-responding lesions.\n\nAt a median follow-up of 42.1 months three-year event-free survival was 92.1 percent with brentuximab vedotin against 82.5 percent with standard care (hazard ratio 0.41). Radiotherapy use (53.4 against 56.8 percent) and toxic effects were similar; three-year overall survival was 99.3 and 98.5 percent.","asOf":"2026-09-22","links":[{"label":"N Engl J Med 2022","url":"https://doi.org/10.1056/NEJMoa2206660"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/36322844/"}],"tags":[],"related":[],"cancers":["hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["brentuximab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["ahod1331"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2022,"doi":"10.1056/NEJMoa2206660","pmid":"36322844","authors":"Castellino SM, Pei Q, Parsons SK, et al.","paperType":"rct","findings":["Three-year event-free survival 92.1 percent (95% CI 88.4 to 94.7) versus 82.5 percent (77.4 to 86.5); hazard ratio 0.41 (0.25 to 0.67), p < 0.001.","Three-year overall survival 99.3 versus 98.5 percent.","Involved-site radiotherapy given to 53.4 versus 56.8 percent; toxic effects similar."],"whatItMeans":"Brentuximab vedotin with AVEPC is the new standard for high-risk paediatric Hodgkin lymphoma and led to the first paediatric approval of the drug in November 2022.","caveats":["Open-label; the trial did not reduce radiotherapy use, which later trials are testing."],"changedPractice":true,"participants":600},"route":"/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/","neighbours":{"cancer":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"drug":[{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"}],"trial":[{"id":"ahod1331","kind":"trial","name":"AHOD1331","route":"/trials/ahod1331/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}